61.53
-0.75 (-1.20%)
| Penutupan Terdahulu | 62.28 |
| Buka | 62.32 |
| Jumlah Dagangan | 403,010 |
| Purata Dagangan (3B) | 554,330 |
| Modal Pasaran | 3,359,878,144 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.62 |
| Harga / Jualan (P/S) | 2.60 |
| Harga / Buku (P/B) | 3.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | -17.42% |
| Margin Operasi (TTM) | 15.54% |
| EPS Cair (TTM) | -4.07 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 242.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 65.54% |
| Nisbah Semasa (MRQ) | 1.58 |
| Aliran Tunai Operasi (OCF TTM) | 197.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 782.12 M |
| Pulangan Atas Aset (ROA TTM) | 4.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | LivaNova PLC | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.38 |
|
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.38% |
| % Dimiliki oleh Institusi | 102.95% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 81.00 (Keybanc, 31.64%) | Beli |
| Median | 70.00 (13.77%) | |
| Rendah | 67.00 (Barclays, 8.89%) | Pegang |
| Purata | 72.00 (17.02%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 62.03 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 09 Jan 2026 | 67.00 (8.89%) | Pegang | 64.41 |
| Stifel | 07 Jan 2026 | 70.00 (13.77%) | Beli | 64.62 |
| Keybanc | 19 Dec 2025 | 81.00 (31.64%) | Beli | 62.82 |
| Mizuho | 17 Dec 2025 | 72.00 (17.02%) | Beli | 63.08 |
| 13 Nov 2025 | 70.00 (13.77%) | Beli | 55.20 | |
| Baird | 13 Nov 2025 | 70.00 (13.77%) | Beli | 55.20 |
| 06 Nov 2025 | 63.00 (2.39%) | Beli | 49.57 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Jan 2026 | Pengumuman | LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results |
| 23 Dec 2025 | Pengumuman | LivaNova to Present at J.P. Morgan Healthcare Conference in January |
| 03 Dec 2025 | Pengumuman | LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting |
| 02 Dec 2025 | Pengumuman | LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea |
| 25 Nov 2025 | Pengumuman | LivaNova to Present at Piper Sandler Healthcare Conference in December |
| 24 Nov 2025 | Pengumuman | LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services |
| 12 Nov 2025 | Pengumuman | LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day |
| 05 Nov 2025 | Pengumuman | LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |